Eli Lilly and Company (NYSE:LLY) Shares Sold by KG&L Capital Management LLC

KG&L Capital Management LLC decreased its position in Eli Lilly and Company (NYSE:LLY - Free Report) by 6.5% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 4,900 shares of the company's stock after selling 343 shares during the period. Eli Lilly and Company comprises 1.3% of KG&L Capital Management LLC's portfolio, making the stock its 18th largest holding. KG&L Capital Management LLC's holdings in Eli Lilly and Company were worth $4,047,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in LLY. Mascagni Wealth Management Inc. acquired a new stake in shares of Eli Lilly and Company in the fourth quarter valued at about $43,000. Prudent Man Investment Management Inc. acquired a new position in Eli Lilly and Company during the fourth quarter worth about $48,000. Highline Wealth Partners LLC grew its position in Eli Lilly and Company by 53.3% during the first quarter. Highline Wealth Partners LLC now owns 69 shares of the company's stock worth $57,000 after buying an additional 24 shares during the period. Capital A Wealth Management LLC purchased a new stake in shares of Eli Lilly and Company during the 4th quarter worth approximately $63,000. Finally, Bellwether Advisors LLC acquired a new stake in shares of Eli Lilly and Company in the 4th quarter worth approximately $66,000. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Trading Down 2.4%

Eli Lilly and Company stock traded down $18.94 during trading on Friday, hitting $776.18. The company's stock had a trading volume of 4,109,419 shares, compared to its average volume of 3,675,428. The stock's fifty day moving average is $781.50 and its 200 day moving average is $800.11. Eli Lilly and Company has a 1-year low of $677.09 and a 1-year high of $972.53. The stock has a market capitalization of $735.61 billion, a price-to-earnings ratio of 63.16, a P/E/G ratio of 1.16 and a beta of 0.40. The company has a debt-to-equity ratio of 2.18, a quick ratio of 1.06 and a current ratio of 1.37.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The company reported $3.34 EPS for the quarter, missing analysts' consensus estimates of $4.64 by ($1.30). The company had revenue of $12.73 billion for the quarter, compared to analyst estimates of $12.77 billion. Eli Lilly and Company had a net margin of 22.67% and a return on equity of 85.51%. The company's revenue was up 45.2% compared to the same quarter last year. During the same period in the prior year, the company earned $2.58 EPS. As a group, equities research analysts predict that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, September 10th. Shareholders of record on Friday, August 15th will be issued a $1.50 dividend. The ex-dividend date is Friday, August 15th. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.77%. Eli Lilly and Company's dividend payout ratio (DPR) is presently 48.82%.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the company. HSBC downgraded Eli Lilly and Company from a "buy" rating to a "reduce" rating and dropped their price objective for the company from $1,150.00 to $700.00 in a research note on Monday, April 28th. The Goldman Sachs Group upgraded Eli Lilly and Company from a "neutral" rating to a "buy" rating and dropped their price target for the company from $892.00 to $888.00 in a research report on Tuesday, April 8th. UBS Group cut their price target on Eli Lilly and Company from $1,100.00 to $1,050.00 and set a "buy" rating for the company in a research note on Friday, May 2nd. Wells Fargo & Company reiterated an "overweight" rating on shares of Eli Lilly and Company in a research report on Thursday, May 1st. Finally, Hsbc Global Res downgraded shares of Eli Lilly and Company from a "strong-buy" rating to a "moderate sell" rating in a report on Monday, April 28th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and seventeen have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $1,011.61.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.